RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $235.

February 14, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Alnylam Pharmaceuticals with a $235 price target.
The reiteration of an Outperform rating and a maintained price target of $235 by a reputable analyst like Luca Issi from RBC Capital is likely to instill confidence among investors and could positively influence Alnylam Pharmaceuticals' stock price in the short term. The high relevance and importance scores reflect the direct impact of this analyst rating on ALNY, and the confidence score is high due to the clear and direct nature of the recommendation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100